Glucagon-like peptide-1 (GLP-1) agonist are a family of medications that help manage blood sugar in patients with type 2 ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The drugs include Mounjaro, also known as tirzepatide, and semaglutide, which is sold under the brand names Wegovy, Ozempic ...

More than half of all adults in the U.S. are eligible for semaglutide (Ozempic, Wegovy, Rybelsus), researchers estimated.

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The study is the first set of global estimates directly linking diabetes prevalence with treatment coverage over a ...

In recent years, interest in these medications—initially developed to treat type 2 diabetes—has exploded ... for GLP-1 ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective ...